Disease Domain | Count |
---|---|
Neoplasms | 10 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 31 |
Diagnostic radiopharmaceuticals | 1 |
Synthetic peptide | 1 |
Target |
Mechanism NOX inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism BRD9 modulators |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism BRD9 modulators |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Oct 2024 |
Sponsor / Collaborator |
Start Date01 May 2024 |
Sponsor / Collaborator |
Start Date01 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
18F-AVT-011 ( P-gp ) | Neoplasms More | Preclinical |
BRD9 modulators(University of Salerno)-compounds 19 ( BRD9 ) | Neoplasms More | Preclinical |
BRD9 modulators(University of Salerno)-compounds 11 ( BRD9 ) | Neoplasms More | Preclinical |
BRD9 modulators(University of Salerno)-compounds 5 ( BRD9 ) | Neoplasms More | Preclinical |
Compound 3 (China Pharmaceutical University) ( KRAS G12D ) | Inflammation More | Preclinical |